ABBVvsALNY
AbbVie IncvsAlnylam Pharmaceuticals Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
AbbVie Inc
$200.95
-12.05%
Alnylam Pharmaceuticals Inc
$313.79
-19.78%
60-day price, rebased to 100
Round-by-round
Valuation upside
-48.60% vs -30.50% to DCF fair value
Balance-sheet strength
Altman Z 2.25 vs 5.77
Fundamental quality
Piotroski 7.00 vs 6.00 (of 9)
Growth + margins
Rule-of-40 37.70 vs 77.70
60-day momentum
-8.25% vs -7.18% price return
Market-cap liquidity
$362.8B vs $41.4B
Verdict
Across6categories,ALNYtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onABBVorALNY
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.